41. Respiratory Syncytial Virus (RSV) By Immunoassay (014548) respiratory syncytial virus (RSV) by Immunoassay(014548). CPT 87899 Related Information http://www.labcorp.com/datasets/labcorp/html/chapter/mono/mb011300.htm

Respiratory Syncytial Virus (RSV) by Immunoassay (014548) CPT Related Information Viral Culture, General Viral Culture, Rapid, Respiratory Virus, Direct Detection by DFA, Adenovirus Virus, Direct Detection by DFA, Herpes Simplex Virus Synonyms RSV by EIA; RSV Testing Special Instructions Submit one specimen per test requested. Specify the exact specimen source/origin (eg, nasopharyngeal aspirate). Indicate a specific test number on the request form. Specimen Nasopharyngeal washes or aspirates, frozen Volume Washes not to exceed 2.5 mL Container Sterile leakproof container Collection Nasopharyngeal wash or aspirate using routine collection and transport procedure. Nasal swabs are not considered as sensitive for RSV detection. Avoid using collection containers with preservatives or transport that may contain interfering substances. Obtain sample during acute phase of illness when greatest amount of viral shedding occurs. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested. Storage Instructions Freeze Causes for Rejection Bacterial swab specimens; specimens received in grossly leaking transport containers; dry specimens; specimens submitted in fixative or additives; specimens received in expired transport media or incorrect transport device; inappropriate specimen transport conditions; specimens received after prolonged delay in transport (usually more than 72 hours); wooden shaft swab in transport device; unlabeled specimen or name discrepancy between the specimen label and the request form

42. Biotrin - Respiratory Syncytial Virus respiratory syncytial virus. ( Biotrin's Distributed Product from Bartels ) Europe Only respiratory syncytial virus Direct Fluorescent Antibody Test. http://www.biotrin.ie/products/infectious/bartels/rsv.html

43. Immunoglobulin For Preventing Respiratory Syncytial Virus Infection (Cochrane Re Abstract also available in Italian. Immunoglobulin for preventing respiratorysyncytial virus infection (Cochrane Review). Wang EEL, Tang NK. ABSTRACT. http://www.update-software.com/abstracts/ab001725.htm

From The Cochrane Library, Issue 1, 2003 Abstract also available in Italian Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review) Wang EEL, Tang NK ABSTRACT Order full review View and/or submit comments What's new in this issue Search abstracts ... About The Cochrane Library A substantive amendment to this systematic review was last made on 10 March 1999. Cochrane reviews are regularly checked and updated if necessary. Background: Respiratory Syncytial virus, the most important cause of lower respiratory tract infections in infants and young children in industrialized countries, is associated with increased morbidity in premature infants with or without bronchopulmonary dysplasia as well as those with congenital heart disease. Because of observations that lower rates of disease occur immediately after birth, presumably due to vertical transmission of maternal antibody, and animal studies where protection from pneumonia was observed through administration of immune globulin, the efficacy of passive prophylaxis in premature infants has been studied. Objectives: This meta-analysis was performed to assess the effects of polyclonal respiratory syncytial virus hyperimmune globulin or monoclonal antibody in preventing RSV hospitalization, receipt of intensive care, mechanical ventilation, and mortality in those with underlying prematurity, bronchopulmonary dysplasia, or congenital heart disease.

44. Ribavirin For Respiratory Syncytial Virus Infection Of The Lower Respiratory Tra Ribavirin for respiratory syncytial virus infection of the lower respiratorytract (Cochrane Review). Randolph AG, Wang EEL. ABSTRACT. http://www.update-software.com/abstracts/ab000181.htm

From The Cochrane Library, Issue 1, 2003 Abstract also available in Italian Spanish Ribavirin for respiratory syncytial virus infection of the lower respiratory tract (Cochrane Review) Randolph AG, Wang EEL ABSTRACT Order full review View and/or submit comments What's new in this issue Search abstracts ... About The Cochrane Library A substantive amendment to this systematic review was last made on 11 January 2000. Cochrane reviews are regularly checked and updated if necessary. Background: Respiratory syncytial virus (RSV) is a common cause of lower respiratory tract infection in infants leading to 100,000 hospitalizations annually. Ribavirin is approved for treatment of these infections, but its use is controversial because of questions on its efficacy, concerns about occupational exposure and its high cost. Objectives: Respiratory syncytial virus (RSV) is a common cause of pneumonia in infants. Ribavirin is the only antiviral therapy available against RSV. The objective of this review was to assess the effects of aerosolized ribavirin for infants with RSV lower respiratory tract infection. Search strategy: We searched MEDLINE from 1975 to 1999, we scanned reference lists of articles, and we contacted experts in the field.

45. 1Up Health > Respiratory Syncytial Virus (RSV) > Causes, Incidence, And Risk Fac Comprehesive information on respiratory syncytial virus (RSV) (RSV). Respiratory syncytialvirus (RSV) Causes, Incidence, and Risk Factors. Alternative names http://www.1uphealth.com/health/respiratory_syncytial_virus_rsv_info.html

1Up Health Respiratory syncytial virus (RSV) Alternative Medicine Clinical Trials ... Health Topics A-Z Search 1Up Health Respiratory syncytial virus (RSV) Information Respiratory syncytial virus (RSV) Causes, Incidence, and Risk Factors Alternative names : RSV Definition : Respiratory syncytial virus (RSV) is a very common virus that causes mild cold-like symptoms in adults and older healthy children. It can cause serious respiratory infections in young babies, especially those born prematurely, who have heart or lung disease, or who are immunocompromised. Causes, Incidence, and Risk Factors RSV is the most common respiratory pathogen in infants and young children. It has infected nearly all infants by the age of two years. Seasonal outbreaks of acute respiratory illness occur each year, on a schedule that is somewhat predictable in each region. The season typically begins in the fall and runs into the spring. RSV is spread easily by physical contact. Touching, kissing, and shaking hands with an infected person can spread RSV. Transmission is usually by contact with contaminated secretions, which may involve tiny droplets or objects that droplets have touched. RSV can live for half an hour or more on hands. The virus can also live up to five hours on countertops and for several hours on used tissues. RSV often spreads very rapidly in crowded households and day care centers. In infants and young children, RSV can cause

46. Respiratory Syncytial Virus respiratory syncytial virus. Childhood Infections respiratory syncytial virus- information about the signs and symptoms, prevention, treatment, and more. http://www.ability.org.uk/Respiratory_Syncytial_Virus.html

"see the ability, not the disability" You to can help support the Ability Project by: Our Aims ... Z Respiratory Syncytial Virus Childhood Infections - Respiratory Syncytial Virus - information about the signs and symptoms, prevention, treatment, and more. Respiratory Syncytial Virus (RSV) Info Center - information resource provides health care professionals and parents access to the latest trends, diagnostic tests. Health Answers - Respiratory Syncytial Virus (RSV) RespiGam (RSV-IGIV) - Respiratory Syncytial Virus Immune Globulin offers protection against RSV and BPD in premature infants. Webmaster . Site Design by Ability "see the ability, not the disability" Acknowledgments

47. JAMA -- Page Not Found Mortality Associated With Influenza and respiratory syncytial virus in the UnitedStates Author Information William W. Thompson, PhD; David K. Shay, MD, MPH http://jama.ama-assn.org/issues/v289n2/abs/joc21709.html

Select Journal or Resource JAMA Archives of Dermatology Facial Plastic Surgery Family Medicine (1992-2000) General Psychiatry Internal Medicine Neurology Ophthalmology Surgery MSJAMA Science News Updates Meetings Peer Review Congress The page you requested was not found. The JAMA Archives Journals Web site has been redesigned to provide you with improved layout, features, and functionality. The location of the page you requested may have changed. To find the page you requested, click here HOME CURRENT ISSUE PAST ISSUES ... HELP Error 404 - "Not Found"

48. BIOPHARMA; Sample Entry; Respiratory Syncytial Virus Mab 169 respiratory syncytial virus Mab. Palivizumab Synagis; MEDI-493;respiratory syncytial virus (RSV) monoclonal antibody, recombinant http://www.biopharma.com/rsv.html

BIOPHARMA: Biopharmaceutical Products in the U.S. Market Sample Product Monograph 169 Respiratory Syncytial Virus Mab Palivizumab - Synagis; MEDI-493; respiratory syncytial virus (RSV) monoclonal antibody, recombinant Status - approved; marketed Organizations Involved Abbott Laboratories ­ world mark. Boehringer Ingelheim Pharma KG ­ Manuf. Protein Design Labs, Inc. ­ Tech. Lonza Biologics plc ­ Tech. University of Glasgow ­ Tech. Cross ref : See the entries for Monoclonal Antibodies and Recombinant Monoclonal Antibodies. See also RSV Immune Globulin (RespiGam), which has largely been replaced by this product. Description : Palivizumab or Synagis is a lyophilized (freeze-dried) formulation of a recombinant humanized (chimeric murine-human) IgG1kappa monoclonal antibody glycoprotein with specificity for an epitope in the A antigenic site of the F (fusion) protein of respiratory syncytial virus (RSV). Palivizumab is expressed from a stable mouse myeloma cell line (NS0) which can produce about 1 gram/liter of culture. Synagis was the first monoclonal antibody product approved in the U.S. for an infectious disease indication. Its initial launch was the most successful of any biopharmaceutical product, in terms of rapid gain of sales and market share. Humanization of the murine monoclonal antibdoy prevents human anti-mouse antibody (HAMA) reactions or recognition of the antibody as foreign (i.e., palivizumab presents itself as a human antibody). Humanized antibodies, such as Synagis, can have a longer in vivo half-life and be less immunogenic than conventional murine monoclonal antibodies. An article describing the development of Synagis was published in the Journal of Infectious Diseases (vol. 176, no. 5, p. 1215-24, November 1997).

49. BioMed Central Full Text Respiratory Syncytial Virus And respiratory syncytial virus and TNFalpha induction of chemokine gene expressioninvolves differential activation of Rel A and NFkappaB1 Laura R Carpenter http://www.biomedcentral.com/1471-2334/2/5/

50. Entrez-PubMed Click here to read respiratory syncytial virus and TNF alpha induction of chemokinegene expression involves differential activation of Rel A and NFkappa B1. http://www.biomedcentral.com/pubmed/11922866

PubMed Nucleotide Protein Genome ... Books Search PubMed Protein Nucleotide Structure Genome PMC OMIM Taxonomy Books PopSet ProbeSet 3D Domains UniSTS Domains SNP Journals UniGene NCBI Web Site for Limits Preview/Index History Clipboard ... Text Version Entrez PubMed Overview FAQ Tutorial New/Noteworthy ... E-Utilities PubMed Services Journals Database MeSH Browser Single Citation Matcher Batch Citation Matcher ... Cubby Related Resources Order Documents NLM Gateway TOXNET Consumer Health ... PubMed Central Summary Brief Abstract Citation ASN.1 MEDLINE XML UI List LinkOut Related Articles Domain Links 3D Domain Links Genome Links ProbeSet Links Nucleotide Links OMIM Links PMC Links Cited in PMC PopSet Links Protein Links SNP Links Structure Links Show: Sort Author Journal Pub Date Text File Clipboard Order BMC Infect Dis 2002 Mar 28;2(1):5 Related Articles, Links Respiratory syncytial virus and TNF alpha induction of chemokine gene expression involves differential activation of Rel A and NF-kappa B1. Carpenter LR, Moy JN, Roebuck KA. Department of Immunology/Microbiology, Rush-Presbyterian-St, Luke's Medical Center Chicago, IL 60612, USA. lcarpent@rush.edu PMID: 11922866 [PubMed - indexed for MEDLINE] Summary Brief Abstract Citation ASN.1

51. Nature Publishing Group pp 54 60 respiratory syncytial virus infection suppresses lung CD8 + T-cell effectoractivity and peripheral CD8 + T-cell memory in the respiratory tract Jun http://www.nature.com/cgi-taf/DynaPage.taf?file=/nm/journal/v8/n1/full/nm0102-54

52. Nature Publishing Group CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein 4. Hall, CBrespiratory syncytial virus A continuing culprit and conundrum. J. Ped. http://www.nature.com/cgi-taf/DynaPage.taf?file=/ni/journal/v2/n8/full/ni0801_73

53. Update: Respiratory Syncytial Virus Activity -- United States, 1997-98 Season Update respiratory syncytial virus Activity United States, 199798 Season. AppendixN prospects for immunizing against respiratory syncytial virus. http://wonder.cdc.gov/wonder/prevguid/m0050267/m0050267.asp

CDC WONDER CDC WONDER Home Utilities Help Contact Us Update: Respiratory Syncytial Virus Activity United States, 1997-98 Season MMWR 46(49);1163-1165 Publication date: 12/12/1997 Table of Contents Article Editorial Note References POINT OF CONTACT FOR THIS DOCUMENT: Figures Percentage of specimens testing positive for ... Article Respiratory syncytial virus (RSV), a common cause of winter outbreaks of acute respiratory disease, results in an estimated 90,000 hospitalizations and 4500 deaths each year from lower respiratory tract disease among infants and young children in the United States (1). Outbreaks occur annually throughout the country (2,3). RSV activity in the United States is monitored by the National Respiratory and Enteric Virus Surveillance System (NREVSS), a voluntary, laboratory-based system. This report summarizes trends in RSV reported by NREVSS for July 1992-June 1997 and presents provisional surveillance results for July-November 1997. These data indicate onset of widespread RSV activity for the 1997-98 season. Since July 1992, a total of 100 clinical and public health laboratories in 47 states have participated in NREVSS and have reported weekly to CDC the number of specimens tested for RSV by the antigen-detection and virus-isolation methods and the number of positive results. RSV activity is considered by NREVSS to have become widespread during the first of 2 consecutive weeks during which at least half of participating laboratories report any RSV detections. This definition generally indicates a mean percentage of specimens positive by antigen detection in excess of 10%.

54. RSV, Respiratory Syncytial Virus The Sleep Tight Video© Help for sleepless parents, Encyclopedia Index R RSV,respiratory syncytial virus, Search. RSV, respiratory syncytial virus. http://www.drhull.com/EncyMaster/R/RSV.html

Help for sleepless parents Encyclopedia Index R RSV, respiratory syncytial virus Search RSV, respiratory syncytial virus RSV is the common abbreviation for respiratory syncytial virus, the causative virus for many common colds, but more importantly for the majority of cases of infant bronchiolitis . It occurs in outbreaks chiefly during the cooler months. In and of itself it is a harmless cold virus but is sometimes mentioned in news stories as a terrible new plague. However, it is one of the most common infections of childhood: one half of all children will have an RSV infection in the first year, and essentially all children have had an RSV infection by age 2. These respiratory infections cause an estimated 120,000 hospital admissions in young children in the US annually. Interest in the virus accelerated in recent years for two reasons: we developed a rapid viral identification test performed on bronchial secretions to confirm the the virus new therapies were developed to treat and now, to prevent the disease; the therapies and preventative treatments are all quite expensive and debate continues about how medically effective and cost effective they are In general, prematures and babies who had other significant respiratory problems in the immediate postnatal period are the target population for the preventative treatment strategies, as well as babies with immune deficiencies or

55. Palivizumab And Respiratory Syncytial Virus Immune Globulin Palivizumab and respiratory syncytial virus immune globulin intravenous for theprophylaxis of respiratory syncytial virus infection in high risk infants http://www.cps.ca/english/statements/ID/id99-06.htm

56. Barnes-Jewish Hospital - Respiratory Syncytial Virus (RSV) Home Page Health Info Infectious Disease RespiratorySyncytial Virus (RSV). respiratory syncytial virus (RSV). http://www.barnesjewish.org/groups/default.asp?NavID=577

57. RSV (Respiratory Syncytial Virus) FAQs At StorkNet's NICU Support Cubby subscribe unsubscribe. RSV (respiratory syncytial virus) FAQs. Q Whatis respiratory syncytial virus (RSV) and how does it affect babies? http://www.storknet.com/cubbies/nicu/rsv.htm

Sponsored this month by: Click here for ad info Join our mailing list for new and updated information! subscribe unsubscribe RSV (Respiratory Syncytial Virus) FAQs Q: What is Respiratory Syncytial Virus (RSV) and how does it affect babies? A: Respiratory Syncytial Virus is the most common respiratory virus in infants and young children. It infects virtually all infants by the age of two. In most infants, the virus causes symptoms resembling those of the common cold. In infants born prematurely and/or with chronic lung disease, RSV can cause a severe or even life-threatening disease. Prior to the introduction of Synagis, RSV disease resulted each year in over 125,000 hospitalizations. There was a high mortality risk in approximately 2 percent of those infants. Q: Is RSV contagious? A: Yes, RSV is highly contagious. Each year, up to 50 percent of infants are infected. The infection can be spread through the air, via coughing and sneezing. Transmission can also occur by touching the respiratory secretions of an infected person, and then rubbing your own eyes, nose, or mouth. RSV can survive for 4-7 hours on surfaces such as cribs and countertops. Transmission may be prevented by standard infection control practices, such as hand washing and proper cleaning. Q: What are the symptoms of RSV disease?

58. Respiratory Syncytial Virus Infection respiratory syncytial virus infection. Definition. Causes and symptoms. Respiratorysyncytial virus is spread through close contact with an infected person. http://www.healthatoz.com/healthatoz/Atoz/ency/respiratory_syncytial_virus_infec

Encyclopedia Index R Home Encyclopedia Encyclopedia Index R Respiratory syncytial virus infection Definition Respiratory syncytial virus (RSV) is a virus that can cause severe lower respiratory infections in children under the age of two, and milder upper respiratory infections in older children and adults. RSV infection is also called bronchiolitis, because it is marked in young children by inflammation of the bronchioles. Bronchioles are the narrow airways that lead from the bronchi to the tiny air sacs (alveoli) in the lungs. The result is wheezing , difficulty breathing, and sometimes fatal respiratory failure Description RSV infection is caused by a group of viruses found worldwide. There are two different subtypes of the virus with numerous different strains. Taken together, these viruses account for a significant number of deaths in infants. RSV infection is primarily a disease of winter or early spring, with waves of illness sweeping through a community. The rate of RSV infection is estimated to be 11.4 cases in every 100 children during their first year of life. In the United States, RSV infection occurs most frequently in infants between the ages of two months and six months. RSV infection shows distinctly different symptoms, depending on the age of the infected person. In children under two, the virus causes a serious lower respiratory infection in the lungs. In older children and healthy adults, it causes a mild upper respiratory infection often mistaken for the

59. Detection Of Bovine Respiratory Syncytial Virus Bovine respiratory syncytial virus (BRSV) is an important......Detection of Bovine respiratory syncytial virus. File 9310. http://www.ksu.edu/tech.transfer/macc/portfol/93-10.htm

Detection of Bovine Respiratory Syncytial Virus File #: Description: Bovine respiratory syncytial virus (BRSV) is an important cause of acute respiratory disease in postweaning calves and cattle affecting primarily the Northern U.S., Canada and Europe. The invention can provide rapid, accurate, and cost effective diagnosis from a simple nasal swab compared to conventional practices of tissue cultures which can take up to 6 days. Technology Status: U.S. Patent issued 6/13/95. Conclusion: The Kansas State University Research Foundation is seeking organizations interested in licensing, developing, and commercializing the technology. For additional information please contact the Mid-America Commercialization Corporation. Last Updated:

60. LLUMC: Respiratory Syncytial Virus (RSV) respiratory syncytial virus (RSV). respiratory syncytial virus (RSV)is a very common virus. This virus is a major cause of infections http://www.llu.edu/llumc/nursing/RSV.htm

Respiratory syncytial virus (RSV) Respiratory syncytial virus (RSV) is a very common virus. This virus is a major cause of infections of the lungs and breathing passages in young children. RSV infections often occur in epidemics, usually from late fall through early spring. The highest rates of RSV infection happen in infants from about two to eight months of age. While most infections are mild, RSV can cause severe illness in infants who were born premature or who have lung problems. RSV is highly contagious. RSV is usually passed from person to person by contact with infected body fluids from the nose or mouth of someone with a RSV infection. RSV is most contagious during the first two to four days of infection, but RSV may be spread for up to three weeks (or longer) after the infection has begun. Following exposure, symptoms start within four to six days. Symptoms range from severe to mild. In adults and children over age three, RSV usually causes upper respiratory tract cold symptoms such as: stuffy or runny nose, sore throat, mild headache, mild cough, fever, and a general "ill" feeling. In children younger than age three, RSV infections are more severe with lower respiratory tract illness like bronchiolitis. Symptoms include high fever, severe cough, wheezing, abnormally rapid breathing, and difficulty breathing. In cases of severe RSV infection, the child may have retractions (drawing in) of the chest muscles and skin between the ribs, which indicates major breathing difficulty. RSV infections usually last about a week but may be longer.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 95    Back | 1  | 2  | 3  | 4  | 5  | Next 20